Resuming Temozolomide After Surgery
Temozolomide should be restarted approximately 14 days after surgery once the wound shows evidence of healing, sutures/staples are removed, there is no significant swelling, erythema, or drainage, and no ongoing infection is present. 1
Timing Based on Surgical Risk
High Bleeding Risk Neurosurgery (Craniotomy for Glioblastoma)
- Wait at least 48-72 hours before resuming any systemic therapy after high bleeding risk intracranial surgery 1, 2
- The standard approach is to restart temozolomide approximately 2 weeks (14 days) postoperatively when wound healing criteria are met 1
- This timing applies to both the concomitant radiotherapy phase and maintenance cycles 3
Required Wound Healing Criteria Before Restart
Before resuming temozolomide, verify all of the following 1:
- Evidence of wound healing is present
- All sutures or staples have been removed
- No significant swelling at the surgical site
- No erythema (redness) at the surgical site
- No drainage from the wound
- No ongoing infection at any site (surgical or non-surgical)
Blood Count Requirements
Do not restart temozolomide until blood counts meet these thresholds 3:
- Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L
- Platelet count ≥ 100 × 10⁹/L
Monitoring Schedule
- Obtain complete blood count (CBC) prior to restarting temozolomide 3
- During concomitant radiotherapy phase: Check CBC weekly 3
- During maintenance cycles: Check CBC on Day 1 and Day 22 of each 28-day cycle 3
- If counts drop below thresholds, check CBC weekly until recovery 3
Dosing After Surgical Interruption
Concomitant Radiotherapy Phase
- Resume at 75 mg/m² daily throughout radiotherapy (42-49 days) 3
- Radiation should be initiated 3-6 weeks after surgery 1
- Temozolomide starts concurrently with radiation 1, 4
Maintenance Phase
- Begin 4 weeks after completing concomitant phase 3
- Cycle 1: Start at 150 mg/m² daily on Days 1-5 of 28-day cycle 3
- Cycles 2-6: May escalate to 200 mg/m² daily on Days 1-5 if no toxicity occurred in Cycle 1 3
Critical Pitfalls to Avoid
Premature Restart
- Never restart temozolomide before adequate hemostasis is established after intracranial surgery 1, 2
- Restarting before 48-72 hours post-surgery increases bleeding risk in high-risk neurosurgical procedures 1, 2
- Inadequate wound healing increases infection risk, which would require another treatment interruption 1
Inadequate Blood Count Recovery
- Severe thrombocytopenia (grade 3-4) occurs in 15-20% of patients receiving temozolomide with radiotherapy 5
- Median duration of severe thrombocytopenia can be 32 days (range 1-389 days) 5
- 10% of patients may require platelet transfusions, with some needing ongoing support for over 6 months 5
- Starting temozolomide with platelets <100 × 10⁹/L significantly increases bleeding complications 5
Bowel Function Considerations
- After any abdominal or bowel surgery, wait until bowel function returns (passing flatus, tolerating diet) before restarting oral temozolomide 1, 6
- Postoperative ileus typically resolves within 24-72 hours but can impair drug absorption if present 1, 6
Special Populations
Elderly Patients (≥65-70 years)
- The same wound healing and blood count criteria apply 7, 8
- Radiochemotherapy with temozolomide is feasible and safe in elderly patients without major comorbidities 7, 8
- Median overall survival of 11-11.5 months in elderly patients treated with concomitant temozolomide and radiotherapy 7, 8
- Extent of surgical resection and performance status are the most important prognostic factors 8
Dose Modifications for Toxicity
If temozolomide was held due to toxicity during prior cycles 3:
- Reduce dose by 50 mg/m² per day for the next cycle
- Permanently discontinue if unable to tolerate 100 mg/m² per day
- For ANC <1.0 × 10⁹/L: Hold until ANC >1.5 × 10⁹/L, then resume at reduced dose
- For platelets <50 × 10⁹/L: Hold until platelets >100 × 10⁹/L, then resume at reduced dose